Vivek Subbiah: ‘Was great to partner with her and the team on the Selpercatinib RET fusion tissue agnostic approval

Vivek Subbiah recently shared on X/Twitter:

“So nice to catch up with the terrific Dr. Jennifer Wright at ASCO GI24! Was great to partner with her and the team on the Selpercatinib RET fusion tissue agnostic approval.

Data continues to show > 50 % response rates in RET + pancreatic cancer.

We share a unique age-agnostic and tissue-agnostic perspective as both of us trained in both Internal Medicine and Pediatrics.
This is our The Lancet Oncology paper that led to the FDA approval.”

View the article.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.